Marketing-authorisation holder · United States
Tersera
6 medicines in 1 country, as authorisation holder.
Group structure
Part of
TerseraPharmaceutical groupOther companies in the group
United States1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Medicines
Every medicine in the registers under its name, current ones first.
6 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| QMIIZ ODT15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet, orally disintegrating | Meloxicam | United States | Not marketed | 2018 |
| VARUBI166.5mg base/92.5ml (eq 1.8mg base/ml) · Emulsion | Rolapitant | United States | Not marketed | 2017 |
| VARUBI90mg base · Tablet | Rolapitant | United States | Marketed | 2015 |
| XERMELO250mg base · Tablet | Telotristat etiprate | United States | Marketed | 2017 |
| ZOLADEX3.6mg · Implant | Goserelin | United States | Marketed | 1995 |
| ZOLADEX10.8mg base | 3.6mg base · Implant | Goserelin | United States | Marketed | 1989 |